Key result
Idarubicin yields ~15% response in relapsed high-grade astrocytoma despite insufficient activity against other brain tumors.
Why the study?
Does idarubicin improve tumor response in children with relapsed brain tumors?
Population
74 children with relapsed brain tumors
Design
Cohort
Authors
Loading...
Idarubicin lacks activity warranting further study in most relapsed pediatric brain tumors; leaves open hypothesis-generating activity in high-grade astrocytoma.
Does idarubicin improve tumor response in children with relapsed brain tumors?
Idarubicin is not sufficiently active against relapsed medulloblastoma, ependymoma, or brain stem tumors to warrant further study in a Phase III setting.
Arndt et al. (1998) studied Relapsed brain tumors (n=74). Idarubicin was evaluated on Response rate for relapsed high grade astrocytoma (95% CI 3.3-40). Idarubicin showed insufficient activity against relapsed medulloblastoma, ependymoma, or brain stem tumors, but yielded a 15% response rate (95% CI, 3.3-40%) in relapsed high grade astrocytoma.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: